In re Application of: Serial No.:

JANJIC ET AL. 08/897,351

JULY 21, 1997

VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) NUCLEIC ACID LIGAND COMPLEXES

DEC 1 1 1998

ASSISANT COMMISSIONER FOR PATENTS Washington, D.C. 20231

c	÷	_	
J	ι	ı	٠

Filed: For:

Transm	itted herewith is an amendment in the above-identified application.
	In the event that a petition under 37 CFR Section 1.136 is required, but not separated submitted,
	applicant(s) hereby petition(s) for such an extension of time.
	Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified
	statement previously submitted.
	A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
	No additional fee is required.

The fee has been calculated as shown below.

	CLAIMS REMAINING AFTER AMDT.		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE (SMALL ENTITY)	ADD'L FEE (SMALL ENTITY)	RATE	ADD'L FEE
TOTAL	21	MINUS	20	•1	x \$9 =	\$	x \$18 =	\$18
INDEP.	2	MINUS	3	0 '	x \$36 =	\$	x \$	\$0 '
[First P	resentation of	Multiple	Dep. Claim	1	+ \$130 =	\$	+ \$260	\$0
				! ! !	TOTAL ADD'L FEE	\$	TOTAL ADD'L FEE	\$18

* ** **	If the entry in Col. 1 is less than the entry in Col. 2, write "O" in Col. 3. If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space. If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.
	It is believed no fees are due. If this is incorrect, please charge by Deposit Account No. 22-0277 for any fees
<u>s</u>	Please authorize the \$18.00 additional claim fee to Deposit Account No. 22-0277 (NeXstar Pharmaceuticals, Inc.)
<u>s</u>	The Commissioner is hereby authorized to charge any underpayment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 22-0277. Any filing under 37 CFR 1.16 for the presentation of extra claims. Any patent application processing fee under 37 CFR 1.17. RECEIVED Respectfully submitted,
	Bay Suptail 7 1998

Suite 200 Englewood, CO 80111

Telephone: (303) 793-3333

Barry J. Swanson, #33,215 Swanson & Bratschun Line USTU: 8400 E. Prentice ANTENIOLE CENTER

37 CFR 1.8

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on

Name: Tracy E. Crispino Signature: